ALNY Yvonne Greenstreet sells $3.2M worth of shares
Aug 20, 2025, 4:34 AM
0.00%
What does ALNY do
Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
Yvonne Greenstreet sold 6,979 shares of ALNY on 18 August at $455.82 per share, worth a total of $3.2M. They now own 63,006 ALNY shares, or a 11% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.